ADORA2A and invasive breast carcinoma: In order to highlight the clinical impact of A2AR and determine its eventual involvement in human breast tumorigenesis, a cohort of 62 invasive breast carcinoma patients with an average age of 51 years (ranging from 32 to 89 years) was included in this study.